Drug Type Small molecule drug |
Synonyms (2S,5R,6R)-6-({[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]carbonyl}amino)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3-(2-Chloro-6-fluorophenyl)-5-methyl-4-isoxazolylpenicillin, Floxacillin + [8] |
Target |
Mechanism PBPs inhibitors(Bacterial penicillin-binding protein inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date CN (17 Apr 2002), |
Regulation- |
Molecular FormulaC19H17ClFN3O5S |
InChIKeyUIOFUWFRIANQPC-JKIFEVAISA-N |
CAS Registry5250-39-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Floxacillin sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Bacterial Infections | CN | 17 Apr 2002 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bacterial Infections | Discovery | DE | 06 Jan 2005 |
Not Applicable | - | 77 | ddegszqkov(xpzktiaqzs) = Only one catheter-related adverse event required medical intervention, and there were no catheter-related infections rxkoxrkpzc (fkfdidqecn ) | - | 13 Mar 2024 | ||
Phase 2 | 60 | objaojbbbn(waexvbbyge) = utnbiwlvdt ezgzplkpsf (iruhpesdjk ) | Positive | 15 Jan 2016 | |||
objaojbbbn(waexvbbyge) = jrhpzmywyy ezgzplkpsf (iruhpesdjk ) |